Biogen Inc (BIIB) support and resistance · P/E 21, rev $9.89B
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
This page maps Biogen Inc (BIIB) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new BIIB 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the BIIB quote page for the session range and the stock page for the full model.
Not investment advice.